Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft

Bone Marrow Transplantation

Volumn 23, Issue 5, 1999, Pages 443-450

  Herrera, C ^a   Torres, A ^a   Garcia Castellano J M ^a   Roman, J ^a   Martin, C ^a   Serrano, J ^a   Falcon, M ^a   Alvarez, M A ^a   Gomez, P ^a   Martinez, F ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

GVHD; Immunosuppression; Post transplant; Selective T cell depletion

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA REMISSION; LYMPHOCYTE DEPLETION; MALE; MULTIPLE MYELOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 0033011056     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701493     Document Type: Article

References (42)

1. Marmont A, Horowitz M, Gale RP et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
2. Mitsuyasu RT, Champlin RE, Gale RP et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease: a prospective, randomized, double-blind trial. Ann Intern Med 1986; 105: 20-26.
3. Hale G, Cobbold S, Waldmann H. T-cell depletion with Campath-1 in allogeneic bone marrow transplantation. Transplantation 1988; 45: 753-759.
4. Kernan N, Bordignon C, Heller G et al. Graft failure following T-cell depleted HLA-identical marrow transplants for leukemia: analysis of risk factors and results of secondary transplants. Blood 1989; 74: 2227-2236.
5. + T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 1990; 76: 418-423.
6. Champlin R, Jansen J, Ho W et al. Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myclogenous leukemia. Transplant Proc 1991; 23: 1695-1696.
7. + cells for prevention of graft-versus-host disease after bone marrow transplantation. Transplantation 1994; 57: 82-87.
8. Jansen J, Hanks S, Akard L et al. Selective T-cell depletion with CD8-conjugated magnetic beads in the prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Leukemia 1995; 9: 271-278.
9. Antin JH, Bierer BE, Smith BR et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991; 78: 2139-2149.
10. Soiffer RJ, Murray C, Mauch P et al. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol 1992; 10: 1191-1200.
11. Verdonck L, Dekker A, de Gast G et al. Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft. Blood 1994; 83: 3090-3096.
12. Drobyski WR, Ash RC, Casper JT et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 1994; 83: 1980-1987.
13. Martin PJ, Donor CD8 cells prevent allogeneic marrow graft rejection in mice. Potential implications for marrow transplantation in humans. J Exp Med 1993; 178: 703-712.
14. Grañena A, Canals C, Picón M et al. GVHD prophylaxis in CML: complete depletion of CD4 cells and controlled numbers of CD8 lymphocytes in the donor marrow. Bone Marrow Transplant 1994; 14 (Suppl. 3): 85 (Abstr.).
15. + cells as a GVHD prophylaxis prevents graft failure in CML patients undergoing allogeneic BMT. Bone Marrow Transplant 1997; 19 (Suppl. 1): 27 (Abstr.).
16. + cell content in donor bone marrow. Blood 1995; 86 (Suppl. 1): 571 (Abstr.).
17. + cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase. Bone Marrow Transplant 1997; 20: 945-952.
18. Weisdorf D, Hakke R, Blazar B et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991; 51: 1197-1203.
19. Bross DS, Tutschka PJ, Farmer ER et al. Predictive factors for acute graft-versus-host disease in patients transplanted with HLA-identical bone marrow. Blood 1984; 63: 1265-1270.
20. Gale RP, Bortin MM, van Bekkum DW et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 67: 397-406.
21. Flowers MED, Pepe MS, Longton G et al. Previous donor pregnancy as a risk factor for acute graft-versus-host disease in patients with aplastic anemia treated by allogeneic marrow transplantation. Br J Haematol 1990; 74: 492-496.
22. Beatty PG, Hansen JA, Longton GM et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 51: 443-447.
23. Przepiorka D, Weisdorf D, Martin P et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
24. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
25. Boerwinkle E, Xiong W, Fourest E, Chan L. Rapid typing of tandemly repeated hypervariable loci by the polymerase chain reaction: application to the apolipoprotein B 3′ hypervariable region. Proc Natl Acad Sci USA 1989; 86: 212-216.
26. Budowle B, Chakraborty R, Giusti AM et al. Analysis of the VNTR locus DIS80 by PCR followed by high-resolution PAGE. Am J Hum Genet 1991; 48: 137-144.
27. Mackinnon S, Barnett L, Bourhis JH et al. Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Blood 1992; 80: 3235-3241.
28. Richards B, Heilig R, Oberle I et al. Rapid PCR analysis of the St14 (DXS52) VNTR. Nucleic Acids Res 1991; 19: 1994.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958: 53: 457-481.
30. Cox DR. Regression models and life-tables. JR Stat Soc 1972; 34: 187-220.
31. Prentice HG, Janossy G, Price-Jones L et al. Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukemic marrow transplant recipients. Lancet 1984; 1: 472-475.
32. Waldmann HG, Hale G, Cividalli G et al. Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (Campath-1). Lancet 1984; 2: 483-486.
33. + T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice. J Exp Med 1987; 165: 1552-1564.
34. OKunewick JP, Kochiban DL, Buffo MJ. Comparative effects of various T cell subtypes on GVHD in a murine model for MHC-matched unrelated donor transplant. Bone Marrow Transplant 1990; 5: 145-152.
35. Hamilton BL. L3T4-positive T-cells participate in the induction of graft-vs-host disease in response to minor histocompatibility antigens. J Immunol 1987; 139: 2511-2515.
36. Pollard CM, Powles RL. Millar JL et al. Leukaemic relapse following Campath-1 treated bone marrow transplantation for leukaemia. Lancet 1986; 2: 1343-1344.
37. Prentice HG, Brenner MK. Donor marrow T cell depletion for prevention of GvHD without loss of the GvL effect. Current results in acute myeloblastic leukemia and future directions. In: Gale RP, Champlin RE (eds). Bone Marrow Transplantation: Current Controversies. Alan R Liss: New York, 1989, pp 117-125.
38. Young JW, Papadopoulos EB, Cunningham I et al. T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Blood 1992; 79: 3380-3387.
39. Apperley JF, Jones L, Hale G et al. Bone marrow transplantation for patient with chronic myeloid leukemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1986; 1: 53-66.
40. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806-814.
41. + T lymphocytes can exert cytotoxicity to chronic myeloid leukemia cells processing and presenting exogenous antigen. Br J Haematol 1996; 93: 606-612.
42. + lymphocyte lines generated in vitro against chronic myelogenous leukemia. Exp Hematol 1995; 23: 1167-1172.